The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged >= 60 Years after Allogeneic Stem Cell Transplant

Context: Allogeneic hematopoietic stem cell transplant (HCT) represents a curative option in acute myeloid leukemia (AML) in patients older then 60 years. The use of reduced intensity conditioning regimens (RIC) has decreased treatment related toxicity and minimized the role of age as a limiting factor. Other variables such as disease status, cytogenetics, donor type and comorbidities gained importance in the pre-transplant risk assessment. In 2014, Sorror et al., proposed a risk-adapted strategy, integrating AML-, HCT- and patient-specific risk factors to guide decisions about HCT versus no HCT in elderly patients.